<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460560</url>
  </required_header>
  <id_info>
    <org_study_id>834744</org_study_id>
    <nct_id>NCT04460560</nct_id>
  </id_info>
  <brief_title>Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)</brief_title>
  <acronym>INFUSE</acronym>
  <official_title>A Multi-Center, Open Label, Collaborative Research Study to Treat HRS-AKI Patients With Continuous Terlipressin Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatorenal syndrome-acute kidney injury (HRS-AKI), a potentially reversible renal failure,&#xD;
      is a serious, rapidly progressing, often fatal, complication of decompensated cirrhosis.&#xD;
      Terlipressin is a synthetic vasopressin analogue that acts as a systemic vasoconstrictor via&#xD;
      the vascular vasopressin V1 receptors. In HRS-AKI patients the strong V1 receptor-mediated&#xD;
      vasoconstrictor activity of terlipressin, particularly in the splanchnic area, increases&#xD;
      effective intravascular volume and mean arterial pressure (MAP), ameliorates&#xD;
      renin-angiotensin-aldosterone system and sympathetic nervous system hyperactivity, and&#xD;
      improves renal blood flow. The INFUSE trial will evaluate the use of continuous terlipressin&#xD;
      infusion in patients on the liver transplant waiting list with HRS-AKI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of renal function (SCr) from Day 1 thru end of treatment, repeated measure analysis. SCr will be collected daily, from Day 1 thru end of treatment. Baseline SCr will also be entered.</measure>
    <time_frame>14 days or reversal of HRS-AKI, whichever occur first</time_frame>
    <description>SCr will be collected daily, from Day 1 thru end of treatment.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatorenal Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.&#xD;
For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent by subject or legally authorized representative.&#xD;
&#xD;
          2. At least 18 years of age.&#xD;
&#xD;
          3. Cirrhosis and ascites.&#xD;
&#xD;
          4. No sustained improvement in renal function (less than 20% decrease in SCr) at least 48&#xD;
             hours after diuretic withdrawal and after plasma volume expansion with albumin (given&#xD;
             daily for two days - 48 hours minimum from 1st dose). If SCr improves by ≥ 20 % but&#xD;
             plateaus ( ≤ 10 % fluctuation in sCr) and remains above 1.5 mg/dl for ≥another 48 hrs&#xD;
             and there are no features of acute tubular necrosis.&#xD;
&#xD;
          5. Increase in SCr by at least ≥ 0.3 mg/dl OR 1.5-2 fold above baseline (AKI stage 1 and&#xD;
             above), to a SCr of ≥ 1.5 mg/dl at the time of initiating treatment. Baseline SCr is&#xD;
             defined as the most recent, lowest SCr within last 6 months before date of current&#xD;
             admission.&#xD;
&#xD;
          6. A.On liver transplant wait list or liver transplant eligible with anticipation of&#xD;
             being placed on the liver transplant wait list. B. Patients not on the transplant&#xD;
             waitlist or transplant eligible are also eligible for the trial ( maximum 25 subjects)&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serum creatinine level greater than 5.0 mg/dL. Subjects with value greater than 5.0&#xD;
             mg/dL may be enrolled with Sponsor prior approval.&#xD;
&#xD;
          2. MELD score ≥ 35&#xD;
&#xD;
          3. Acute on Chronic Liver Failure (ACLF) grade 3 (according to the CLIF Consortium&#xD;
             grading system).&#xD;
&#xD;
          4. Uncontrolled sepsis and/or uncontrolled bacterial infection (e.g., persisting&#xD;
             bacteremia, persisting ascitic fluid leukocytosis, fever, increasing leukocytosis with&#xD;
             vasomotor instability).&#xD;
&#xD;
          5. Shock.&#xD;
&#xD;
          6. Current or recent (within 4 weeks) treatment with or exposure to nephrotoxic agents:&#xD;
             eg, aminoglycosides, amphotericin, cyclosporine A, cisplatin, nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs: e.g., ibuprofen, naproxen, diclofenac), significant&#xD;
             exposure to radiographic contrast agents (large doses or multiple injections of&#xD;
             iodinated contrast media; e.g., during coronary or abdominal angiogram).&#xD;
&#xD;
          7. Estimated life expectancy of less than 7 days.&#xD;
&#xD;
          8. Advanced Hepatocellular Carcinoma ( HCC) with expected survival of &lt; 6 months&#xD;
&#xD;
          9. Superimposed acute liver injury due to drugs (e.g., acetaminophen), dietary&#xD;
             supplements, herbal preparations, viral hepatitis, or toxins (e.g., Amanita toxin with&#xD;
             mushroom poisoning carbon tetrachloride), with the exception of acute alcoholic&#xD;
             hepatitis.&#xD;
&#xD;
         10. Evidence of obstructive uropathy or parenchymal renal disease. Renal ultrasound or&#xD;
             other imaging not required but should be taken if suspicious.&#xD;
&#xD;
         11. Tubular epithelial casts, heme granular casts (range of 1-3 granular casts&#xD;
             acceptable), hematuria or microhematuria on urinalysis that is indicative of acute&#xD;
             tubular necrosis and/or intrinsic renal disease.&#xD;
&#xD;
         12. Subjects known to be pregnant; all women of child-bearing age and potential must have&#xD;
             a negative pregnancy test.&#xD;
&#xD;
         13. Severe cardiovascular disease, including, but not limited to, unstable angina,&#xD;
             pulmonary edema, congestive heart failure, or persisting symptomatic peripheral&#xD;
             vascular disease, myocardial infarction or stable chronic angina within the past 12&#xD;
             months, or any other cardiovascular disease judged by the investigator to be severe&#xD;
             and creates a risk to subject with concurrent terlipressin use.&#xD;
&#xD;
         14. Current or recent (within 4 weeks) renal replacement therapy (RRT) or anticipation of&#xD;
             RRT within 3 days on enrollment.&#xD;
&#xD;
         15. Participation in other clinical research involving investigational medicinal products&#xD;
             within 30 days of starting study drug that would adversely affect participation in&#xD;
             this or the current trial.&#xD;
&#xD;
         16. Transjugular intrahepatic portosystemic shunt (TIPS) within 30 days of starting study&#xD;
             drug.&#xD;
&#xD;
         17. For the Prospective Group: All vasopressors must be stopped prior to treatment with&#xD;
             terlipressin. Use of vasopressors (e.g., norepinephrine, epinephrine or vasopressin&#xD;
             dopamine or other vasopressors) of ≥ 3 consecutive days within the prior 14-day&#xD;
             screening period are excluded. Patients receiving a vasopressor other than midodrine&#xD;
             within 24 hours of qualifying SCr are excluded, i.e, a 24-h washout is required prior&#xD;
             to enrollment.&#xD;
&#xD;
             Note: Patients receiving midodrine and octreotide may be enrolled. Midodrine and&#xD;
             octreotide treatment must be stopped prior to enrollment.&#xD;
&#xD;
         18. Known allergy or sensitivity to terlipressin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Grace Kim-Lee</last_name>
    <phone>215-360-0836</phone>
    <email>gracekim.lee@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Toal</last_name>
      <phone>215-349-8548</phone>
      <email>Emily.Toal@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Ethan Weinberg, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White All Saints Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatorenal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

